Updated Covid-19 QAA No. 9

10th Aug 2020

The RDTC has updated COVID-19 QAA No. 9 - Switching from intravenous to subcutaneous infliximab. Changes to this version include updating to include license extension for Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and psoriasis plus making reference to recently published NICE evidence summary on infliximab SC in rheumatoid arthritis.